CMS Denies Medicare Payment for Warfarin PGx Testing; Proposes Limiting Coverage to Evidence Studies

The CMS decision could signal private payors to hold off on covering genetic testing in this area until large, randomized, prospective studies are completed, yielding more convincing outcomes data.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories